Adage Capital Partners Gp, L.L.C. Janux Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51.6 Billion
- Q1 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,654,574 shares of JANX stock, worth $90.5 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
3,654,574
Previous 3,061,750
19.36%
Holding current value
$90.5 Million
Previous $164 Million
39.81%
% of portfolio
0.19%
Previous 0.3%
Shares
11 transactions
Others Institutions Holding JANX
# of Institutions
193Shares Held
57.3MCall Options Held
626KPut Options Held
155K-
Ra Capital Management, L.P. Boston, MA11.2MShares$277 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$114 Million0.07% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$82.4 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$58 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$56.4 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.03B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...